Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries, such as bladder removal followed by artificial bladder implantation or the use of a urine pouch,
A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors in bladder cancer, a new study finds.
Revolutionary research shows statins combined with new PIN1 inhibitors could transform bladder cancer treatment, offering hope to thousands of patients.
A HALF-HOUR scan could help bladder cancer patients be treated almost twice as fast, a groundbreaking study has found. Using an MRI check to help tackle tumours — instead of invasive surgery — cut
The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed. ... Read More The post Health Check: We’ll see you in court and you bladder believe it,
Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder cancer. Using the immunotherapy drug durvalumab before and after surgery reduced the recurrence of operable bladder cancer by a third,
Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring.
Bladder cancer presents through various symptoms, ranging from subtle changes to more noticeable signs. While some symptoms might seem minor, understanding
A population-based study revealed treatment patterns among patients starting chemotherapy as first-line therapy for metastatic bladder cancer.
Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle-invasive) bladder cancer had significantly less ...
Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges.
ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click for our IBRX stock update.